Laddar...
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced breast and gastric cancer in which HER2 is overexpressed. Several biosimilar versions of trastuzumab are expected to enter t...
Sparad:
| I publikationen: | Br J Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Nature Publishing Group UK
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738325/ https://ncbi.nlm.nih.gov/pubmed/31257362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0480-z |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|